Kala Pharmaceuticals Revenue and Competitors

Claim your profile

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Kala Pharmaceuticals's estimated annual revenue is currently $11.6M per year.(i)
  • Kala Pharmaceuticals received $110.0M in venture funding in October 2018.
  • Kala Pharmaceuticals's estimated revenue per employee is $126,304
  • Kala Pharmaceuticals's total funding is $506.4M.
  • Kala Pharmaceuticals's current valuation is $66.2M. (January 2022)

Employee Data

  • Kala Pharmaceuticals has 92 Employees.(i)
  • Kala Pharmaceuticals grew their employee count by -55% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. For more information, please visit Kala's website at www.kalarx.com.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Security,Wind Power


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Kala Pharmaceuticals News

2022-04-17 - Where Does Wall Street Think Kala Pharmaceuticals Inc (KALA) Stock Will Go?

InvestorsObserver is giving Kala Pharmaceuticals Inc (KALA) an Analyst Rating Rank of 27, meaning KALA is ranked higher by analysts than 27%...

2022-04-06 - Kala Pharmaceuticals to Present Phase 1b Clinical Data for ...

Kala is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for...

2022-03-30 - Kala Pharmaceuticals Reports Fourth Quarter and Full Year ...

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update. Published: Mar 29, 2022. -- Achieved $11.2...

2021-11-15 - Kala Pharmaceuticals Announces Time Change for Third Quarter 2021 Financial Results Conference Call

WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has changed the time of ...

2021-11-15 - Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Diseases

-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing -- -- KPI-012 demonstrated positive safety and efficacy results in PCED Phase 1b clinical trial -- -- Kala expects to init ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Kala Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2012-03-15$6.2MUndisclosedLux Capital, Polaris Venture PartnersArticle
2013-03-01$11.5MACrown Venture Fund LLCArticle
2014-04-24$22.5MBYsios CapitalArticle
2016-04-14$68.0MCLongitude CapitalArticle
2018-10-03$110.0MUndisclosedAthyrium Capital ManagementArticle